Gilead Sciences ended the fourth quarter with results that exceeded Wall Street revenue expectations, yet the market ...

Gilead has secured another synthetic lethal therapy, handing over $80 million upfront for the global rights to a clinic-ready cancer drug from China’s Genhouse Bio. | Gilead has secured another ...

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 7.55% on an annualized basis producing an average annual return of 19.59%. Currently, Gilead Sciences has a market ...

Will the recent momentum be cut short following the biotech's Feb. 10 earnings release, or will it continue?

Gilead Sciences (NASDAQ:GILD) executives highlighted what they described as a “remarkable year” of clinical, commercial, and ...

By Deena Beasley Feb 10 (Reuters) - Gilead Sciences on Tuesday issued a 2026 financial forecast that was at the low end of ...

(Reuters) -Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as an initial treatment, according to trial results presented on ...

GIlead Sciences (GILD) stock is trading at record highs after announcing a top- and bottom-line beat for the fourth quarter ...

Gilead Sciences is coming off of a milestone year that saw the start of the much-anticipated launch of the world’s first twice-yearly injectable HIV pre-exposure prophylaxis (PrEP) medicine Ye | ...

Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead Sciences for $14 million upfront, plus the chance to net up to $400 million in biobucks. Last year, ...

Gilead Sciences, Inc.'s ( NASDAQ:GILD ) dividend will be increasing from last year's payment of the same period ...

The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.